Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12282251 | 0.84 | KMT2A (0.54) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL10140834 | 0.82 | KMT2A (0.51) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL890107 | 0.80 | KMT2A (0.56) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL753109 | 0.79 | KMT2A (0.57) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL890075 | 0.79 | MEN1 (0.54) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL888760 | 0.78 | KMT2A (0.54) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL19364663 | 0.77 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL13747641 | 0.77 | ALDH1A1 (0.53) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL755778 | 0.77 | KMT2A (0.55) | KMT2AMEN1ALDH1A1VEGFAEGLN1 | |
| SCHEMBL8907285 | 0.77 | KMT2A (0.52) | KMT2AMEN1ALDH1A1VEGFAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | KMT2A 1865/4885MEN1 4868/4885ALDH1A1 201/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | KMT2A 1492/4885MEN1 4840/4885ALDH1A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.